Has it been 10 years already that INHX (coming in at 163% premium) was purchased by BMY to get into the lucrative HCV market?
Like a scorned lover BMY.... decided to take revenge against GILD (who spurned BMY's daclatasvir) and purchase their own nuke to win a place in the HCV market.